{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:24:12Z","timestamp":1787840652773,"version":"build-2784847793"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>\n                    Rosai-Dorfman disease (RDD) typically presents as bulky lymphadenopathy. Somatic mutations in RAS\/MAP kinase pathway genes are common but germline mutations are rare. A patient with RDD and exocrine pancreatic insufficiency was found to have a homozygous germline mutation in\n                    <jats:italic toggle=\"yes\">SLC29A3<\/jats:italic>\n                    , which has been associated with the Histiocytosis\/Lymphadenopathy Plus Syndrome. His RDD also was positive for a somatic mutation in\n                    <jats:italic toggle=\"yes\">lymphoid enhancer binding factor 1 (LEF1)<\/jats:italic>\n                    . The concurrence of RDD and pancreatic insufficiency should raise consideration of\n                    <jats:italic toggle=\"yes\">SLC29A3<\/jats:italic>\n                    mutations. Other cases will be needed to confirm this observation and a possible contribution of\n                    <jats:italic toggle=\"yes\">LEF1<\/jats:italic>\n                    to the development of RDD.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000001889","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T04:38:41Z","timestamp":1596861521000},"page":"e689-e691","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Rosai-Dorfman Disease and Exocrine Pancreatic Insufficiency in a Patient With a Germline SLC29A3 Mutation"],"prefix":"10.1097","volume":"43","author":[{"given":"Julie","family":"Blatt","sequence":"first","affiliation":[{"name":"Pediatric Hematology Oncology"},{"name":"The Lineberger Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Parekh","sequence":"additional","affiliation":[{"name":"UNC Rex Health, Hematopathology, The University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford C.","family":"Powell","sequence":"additional","affiliation":[{"name":"Cancer Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Fedoriw","sequence":"additional","affiliation":[{"name":"Hematopathology"},{"name":"The Lineberger Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Reddy","sequence":"additional","affiliation":[{"name":"Raleigh Medical Group, Gastroenterology, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Hematopathology"},{"name":"The Lineberger Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","article-title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","volume":"131","author":"Abla","year":"2018","journal-title":"Blood"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/bloodadvances.2019000093","article-title":"BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor","volume":"3","author":"Mastropolo","year":"2019","journal-title":"Blood Adv"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","article-title":"Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease","volume":"30","author":"Garces","year":"2017","journal-title":"Mod Pathol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"2512","author":"Durham","year":"2019","journal-title":"Nat Med"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"e1000833","DOI":"10.1371\/journal.pgen.1000833","article-title":"Mutations in SLC29A3, endoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad Histiocytosis) and familial Rosai-Dorfman disease","volume":"6","author":"Morgan","year":"2010","journal-title":"Plos Genetics"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"e29708","DOI":"10.1371\/journal.pone.0029708","article-title":"A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant","volume":"7","author":"Bolze","year":"2012","journal-title":"PLoS One"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamadermatol.2019.4984","article-title":"Treatment of childhood-onset lupus erythematosus panniculitis with rituximab","volume":"156","author":"Correll","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R8-20250804","first-page":"1389","article-title":"Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment","volume":"7","author":"Santiago","year":"2017","journal-title":"Am J Cancer Res"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/187153007780059450","article-title":"Epigenetic alterations of the Wnt\/beta-catenin pathway in human disease","volume":"7","author":"Aguilera","year":"2007","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMc1713676","article-title":"Rosai-Dorfman disease with activating KRAS mutation\u2014response to cobimetinib","volume":"377","author":"Jacobsen","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"e20163148","DOI":"10.1542\/peds.2016-3148","article-title":"Tocilizumab for the treatment of SLC29A3 mutation positive PHID syndrome","volume":"140","author":"Rafiq","year":"2017","journal-title":"Pediatrics"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:10:56Z","timestamp":1754338256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001889","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"2020-03-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}